AURO LABORATORIES SHARE PRICE

Auro Laboratories Ltd, founded in 1992, has been manufacturing and providing generic Active Pharmaceutical Ingredients (API). Currently, the Company is specializing in producing Anti Diabetics like Metformin HCL. It is the first-line treatment for type 2 diabetes. The Company is headquartered in Mumbai and it has manufacturing facility at Palghar in Maharashtra. The facility has all the required certifications from Indian authorities and European registration organization Since inception, the Company focused on providing quality pharmaceuticals while maintaining high manufacturing standards. Company presently has 1800 MTPA of Metformin HCL manufacturing capacity, with projects underway to expand the capacity to 3600 MTPA. The Company`s primary focus was on Anti-Diabetic Drugs, which estimated to be one of the fastest growing therapeutic segments. Currently, it manufacture Metformin Hydrochloride and Glibenclamide and are on the anvil of introducing others within this segment. Additionally, it also undertake Toll/Custom Manufacturing for API`s and Intermediates on contract basis. The manufacturing facility operates are per cGMP norms and has an installed capacity in excess of 500 Tonnes per annum. Auro laboratories has made its presence felt in international markets with a bulk of it production being exported to South East Asia, Middle East and several European Countries. Some of the countries the company exports to are Egypt, Germany, Malaysia, Singapore, South Africa, Brazil, Spain and United Kingdom. The Company received ISO 9001:2000 and WHO - cGMPs certification. It also received CERTIFICATE OF SUITABILITY (COS) from the European Directorate of Quality Medicine (EDQM) in September 2006.

Auro Laboratories share price as on 25 Apr 2025 is Rs. 249. Over the past 6 months, the Auro Laboratories share price has increased by 5.67% and in the last one year, it has increased by 23.3%. The 52-week low for Auro Laboratories share price was Rs. 156.4 and 52-week high was Rs. 307.2.

Auro Laboratories Ltd, founded in 1992, has been manufacturing and providing generic Active Pharmaceutical Ingredients (API). Currently, the Company is specializing in producing Anti Diabetics like Metformin HCL. It is the first-line treatment for type 2 diabetes. The Company is headquartered in Mumbai and it has manufacturing facility at Palghar in Maharashtra. The facility has all the required certifications from Indian authorities and European registration organization Since inception, the Company focused on providing quality pharmaceuticals while maintaining high manufacturing standards. Company presently has 1800 MTPA of Metformin HCL manufacturing capacity, with projects underway to expand the capacity to 3600 MTPA. The Company`s primary focus was on Anti-Diabetic Drugs, which estimated to be one of the fastest growing therapeutic segments. Currently, it manufacture Metformin Hydrochloride and Glibenclamide and are on the anvil of introducing others within this segment. Additionally, it also undertake Toll/Custom Manufacturing for API`s and Intermediates on contract basis. The manufacturing facility operates are per cGMP norms and has an installed capacity in excess of 500 Tonnes per annum. Auro laboratories has made its presence felt in international markets with a bulk of it production being exported to South East Asia, Middle East and several European Countries. Some of the countries the company exports to are Egypt, Germany, Malaysia, Singapore, South Africa, Brazil, Spain and United Kingdom. The Company received ISO 9001:2000 and WHO - cGMPs certification. It also received CERTIFICATE OF SUITABILITY (COS) from the European Directorate of Quality Medicine (EDQM) in September 2006.

Auro Laboratories share price as on 25 Apr 2025 is Rs. 249. Over the past 6 months, the Auro Laboratories share price has increased by 5.67% and in the last one year, it has increased by 23.3%. The 52-week low for Auro Laboratories share price was Rs. 156.4 and 52-week high was Rs. 307.2.